Brighten Optix Corporation (TPEX:6747)

Market Cap	3.84B
Revenue (ttm)	766.93M
Net Income (ttm)	149.79M
Shares Out	27.20M
EPS (ttm)	5.49
PE Ratio	25.68
Forward PE	n/a
Dividend	9.19 (6.50%)
Ex-Dividend Date	Apr 17, 2025

Volume	13,570
Average Volume	11,694
Open	141.50
Previous Close	141.50
Day's Range	141.00 - 141.50
52-Week Range	124.00 - 164.50
Beta	0.15
RSI	54.03
Earnings Date	May 15, 2025

About Brighten Optix

Brighten Optix Corporation researches, develops, manufactures, and sells contact lenses in Taiwan and internationally. The company offers orthokeratology, a non-invasive and reversible method of vision correction by using a hard contact lens to alter the shape of the front surface of the cornea; gas permeable lenses for single vison, multifocal, and irregular cornea and keratoconus correction, under the HiClear, So2clear, Menicon, Duette, ROSE K, Ampleye, MAXIM 3D, AND ULTRAHEALTH brand name; and soft contact lenses under the iDealsoft, Briomoi...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1965
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6747

Financial Performance

In 2024, Brighten Optix's revenue was 766.93 million, an increase of 2.63% compared to the previous year's 747.30 million. Earnings were 149.79 million, a decrease of -24.82%.